IL-25 in Atopic Dermatitis: A Possible Link between Inflammation and Skin Barrier Dysfunction?
Malene Hvid(Aarhus University), Mette Deleuran(Aarhus University Hospital), Bent Deleuran(Aarhus University), Christian Vestergaard(Aarhus University), Gitte B. Christensen(Leo Pharma (Denmark)), Kaare Kemp(Leo Pharma (Denmark))
Cited by 214
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.5k
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419
Association of Family History of Autoimmune Diseases and Autism Spectrum Disorders
|PEDIATRICS|2009|409
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
|Journal of Investigative Dermatology|2016|377